HBM-7008

N/A

Report date: 2024/04/26 16:35:32

Base Information

Drug NameHBM-7008
Drug Alias NameHBM7008HBM-7008R-7008CLN-418
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsV-set domain-containing T-cell activation inhibitor 1 inhibitors
TargetsTumor necrosis factor receptor superfamily member 9V-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbour Biomed
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnd Platinum Pharmaceutical(Shanghai) Co LtdHarbour BiomedCullinan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A